PROTHENA CORPORATION PUBLIC LIMITED COMPANY Stock-Based Compensation
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Stock-Based Compensation of $7.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $7.88M, a 36.56% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $6.92M, a 36.84% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $7.07M, a 32.76% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $7.20M, a 34.67% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, noncash expense for fiscal 2025 was $37.64M, a 18.11% decline from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, noncash expense for fiscal 2024 was $45.96M, a 12.34% increase from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, noncash expense for fiscal 2023 was $40.91M, a 30.62% increase from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based payment arrangement, noncash expense for fiscal 2022 was $31.32M, a 27.03% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.88M 10-Q · filed 2026-08-06 | $14.79M 10-Q · filed 2026-08-06 | $21.87M derived: sum of 3 quarters · filed 2026-08-06 | $29.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.92M 10-Q · filed 2026-05-07 | $13.99M derived: sum of 2 quarters · filed 2026-05-07 | $21.19M derived: sum of 3 quarters · filed 2026-05-07 | $33.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $14.27M derived: sum of 2 quarters · filed 2026-02-27 | $26.69M derived: sum of 3 quarters · filed 2026-08-06 | $37.64M 10-K · filed 2026-02-27 |
| 2025-09-30 | $7.20M 10-Q · filed 2025-11-06 | $19.62M derived: sum of 2 quarters · filed 2026-08-06 | $30.57M 10-Q · filed 2025-11-06 | $41.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $12.42M 10-Q · filed 2026-08-06 | $23.37M 10-Q · filed 2026-08-06 | $33.89M derived: sum of 3 quarters · filed 2026-08-06 | $44.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $10.95M 10-Q · filed 2026-05-07 | $21.47M derived: sum of 2 quarters · filed 2026-05-07 | $32.49M derived: sum of 3 quarters · filed 2026-05-07 | $44.53M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $10.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $21.54M derived: sum of 2 quarters · filed 2026-02-27 | $33.58M derived: sum of 3 quarters · filed 2026-02-27 | $45.96M 10-K · filed 2026-02-27 |
| 2024-09-30 | $11.02M 10-Q · filed 2025-11-06 | $23.06M derived: sum of 2 quarters · filed 2025-11-06 | $35.44M 10-Q · filed 2025-11-06 | $46.52M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $12.04M 10-Q · filed 2025-08-04 | $24.42M 10-Q · filed 2025-08-04 | $35.50M derived: sum of 3 quarters · filed 2026-02-27 | $46.45M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $12.38M 10-Q · filed 2025-05-08 | $23.46M derived: sum of 2 quarters · filed 2026-02-27 | $34.41M derived: sum of 3 quarters · filed 2026-02-27 | $44.51M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $11.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $22.02M derived: sum of 2 quarters · filed 2026-02-27 | $32.12M derived: sum of 3 quarters · filed 2026-02-27 | $40.91M 10-K · filed 2026-02-27 |
| 2023-09-30 | $10.94M 10-Q · filed 2024-11-12 | $21.04M derived: sum of 2 quarters · filed 2024-11-12 | $29.83M 10-Q · filed 2024-11-12 | $37.27M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $10.10M 10-Q · filed 2024-08-08 | $18.89M 10-Q · filed 2024-08-08 | $26.32M derived: sum of 3 quarters · filed 2025-02-27 | $34.29M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $8.79M 10-Q · filed 2024-05-08 | $16.22M derived: sum of 2 quarters · filed 2025-02-27 | $24.19M derived: sum of 3 quarters · filed 2025-02-27 | $32.45M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $7.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $15.40M derived: sum of 2 quarters · filed 2025-02-27 | $23.66M derived: sum of 3 quarters · filed 2025-02-27 | $31.32M 10-K · filed 2025-02-27 |
| 2022-09-30 | $7.97M 10-Q · filed 2023-11-02 | $16.23M derived: sum of 2 quarters · filed 2023-11-02 | $23.89M 10-Q · filed 2023-11-02 | $30.78M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $8.26M 10-Q · filed 2023-08-03 | $15.92M 10-Q · filed 2023-08-03 | $22.81M derived: sum of 3 quarters · filed 2024-02-22 | $28.86M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $7.66M 10-Q · filed 2023-05-04 | $14.55M derived: sum of 2 quarters · filed 2024-02-22 | $20.60M derived: sum of 3 quarters · filed 2024-02-22 | $26.14M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $6.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $12.94M derived: sum of 2 quarters · filed 2024-02-22 | $18.48M derived: sum of 3 quarters · filed 2024-02-22 | $24.66M 10-K · filed 2024-02-22 |
| 2021-09-30 | $6.05M 10-Q · filed 2022-11-03 | $11.60M derived: sum of 2 quarters · filed 2022-11-03 | $17.77M 10-Q · filed 2022-11-03 | $22.98M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $5.54M 10-Q · filed 2022-08-08 | $11.72M 10-Q · filed 2022-08-08 | $16.92M derived: sum of 3 quarters · filed 2023-02-28 | $22.51M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $6.18M 10-Q · filed 2022-05-05 | $11.38M derived: sum of 2 quarters · filed 2023-02-28 | $16.97M derived: sum of 3 quarters · filed 2023-02-28 | $22.65M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $5.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $10.79M derived: sum of 2 quarters · filed 2023-02-28 | $16.48M derived: sum of 3 quarters · filed 2023-02-28 | $22.01M 10-K · filed 2023-02-28 |
| 2020-09-30 | $5.58M 10-Q · filed 2021-11-04 | $11.27M derived: sum of 2 quarters · filed 2021-11-04 | $16.81M 10-Q · filed 2021-11-04 | $22.09M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $5.69M 10-Q · filed 2021-08-05 | $11.22M 10-Q · filed 2021-08-05 | $16.51M derived: sum of 3 quarters · filed 2022-02-25 | $22.33M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $5.54M 10-Q · filed 2021-05-11 | $10.82M derived: sum of 2 quarters · filed 2022-02-25 | $16.64M derived: sum of 3 quarters · filed 2022-02-25 | $22.92M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $5.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $11.10M derived: sum of 2 quarters · filed 2022-02-25 | $17.38M derived: sum of 3 quarters · filed 2022-02-25 | $23.59M 10-K · filed 2022-02-25 |
| 2019-09-30 | $5.82M 10-Q · filed 2020-11-04 | $12.09M derived: sum of 2 quarters · filed 2020-11-04 | $18.30M 10-Q · filed 2020-11-04 | $22.54M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $6.28M 10-Q · filed 2020-08-06 | $12.48M 10-Q · filed 2020-08-06 | $16.73M derived: sum of 3 quarters · filed 2021-02-26 | $23.77M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $6.21M 10-Q · filed 2020-05-06 | $10.45M derived: sum of 2 quarters · filed 2021-02-26 | $17.49M derived: sum of 3 quarters · filed 2021-02-26 | $26.31M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $11.29M derived: sum of 2 quarters · filed 2021-02-26 | $20.11M derived: sum of 3 quarters · filed 2021-02-26 | $27.01M 10-K · filed 2021-02-26 |
| 2018-09-30 | $7.04M 10-Q · filed 2019-11-05 | $15.86M derived: sum of 2 quarters · filed 2019-11-05 | $22.77M 10-Q · filed 2019-11-05 | $30.17M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-06-30 | $8.82M 10-Q · filed 2019-08-06 | $15.72M 10-Q · filed 2019-08-06 | $23.13M derived: sum of 3 quarters · filed 2020-03-03 | $30.23M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-03-31 | $6.90M 10-Q · filed 2019-05-07 | $14.31M derived: sum of 2 quarters · filed 2020-03-03 | $21.41M derived: sum of 3 quarters · filed 2020-03-03 | $28.06M derived: sum of 4 quarters · filed 2020-03-03 |
| 2017-12-31 | $7.41M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $14.51M derived: sum of 2 quarters · filed 2020-03-03 | $21.16M derived: sum of 3 quarters · filed 2020-03-03 | $26.76M 10-K · filed 2020-03-03 |
| 2017-09-30 | $7.10M 10-Q · filed 2018-11-06 | $13.76M derived: sum of 2 quarters · filed 2018-11-06 | $19.36M 10-Q · filed 2018-11-06 | $24.57M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $6.65M 10-Q · filed 2018-08-07 | $12.26M 10-Q · filed 2018-08-07 | $17.47M derived: sum of 3 quarters · filed 2019-03-15 | $28.91M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $5.60M 10-Q · filed 2018-05-09 | $10.81M derived: sum of 2 quarters · filed 2019-03-15 | $22.26M derived: sum of 3 quarters · filed 2019-03-15 | $26.81M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | $5.21M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $16.66M derived: sum of 2 quarters · filed 2019-03-15 | $21.20M derived: sum of 3 quarters · filed 2019-03-15 | $24.93M 10-K · filed 2019-03-15 |
| 2016-09-30 | $11.45M 10-Q · filed 2017-11-07 | $15.99M derived: sum of 2 quarters · filed 2017-11-07 | $19.72M 10-Q · filed 2017-11-07 | $23.00M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $4.55M 10-Q · filed 2017-08-09 | $8.27M 10-Q · filed 2017-08-09 | $11.55M derived: sum of 3 quarters · filed 2018-02-26 | $14.56M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | $3.72M 10-Q · filed 2017-05-09 | $7.00M derived: sum of 2 quarters · filed 2018-02-26 | $10.02M derived: sum of 3 quarters · filed 2018-02-26 | $12.44M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | $3.28M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $6.29M derived: sum of 2 quarters · filed 2018-02-26 | $8.71M derived: sum of 3 quarters · filed 2018-02-26 | $10.41M 10-K · filed 2018-02-26 |
| 2015-09-30 | $3.02M 10-Q · filed 2016-11-02 | $5.43M derived: sum of 2 quarters · filed 2016-11-02 | $7.14M 10-Q · filed 2016-11-02 | $8.53M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | $2.42M 10-Q · filed 2016-08-02 | $4.12M 10-Q · filed 2016-08-02 | $5.52M derived: sum of 3 quarters · filed 2017-02-27 | $6.93M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $1.70M 10-Q · filed 2016-05-04 | $3.10M derived: sum of 2 quarters · filed 2017-02-27 | $4.52M derived: sum of 3 quarters · filed 2017-02-27 | $5.96M derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $2.82M derived: sum of 2 quarters · filed 2017-02-27 | $4.25M derived: sum of 3 quarters · filed 2017-02-27 | $5.60M 10-K · filed 2017-02-27 |
| 2014-09-30 | $1.42M 10-Q · filed 2015-11-02 | $2.86M derived: sum of 2 quarters · filed 2015-11-02 | $4.20M 10-Q · filed 2015-11-02 | $5.29M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $1.44M 10-Q · filed 2015-08-05 | $2.78M 10-Q · filed 2015-08-05 | $3.87M derived: sum of 3 quarters · filed 2016-02-25 | $4.83M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $1.34M 10-Q · filed 2015-05-06 | $2.43M derived: sum of 2 quarters · filed 2016-02-25 | $3.39M derived: sum of 3 quarters · filed 2016-02-25 | $4.13M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $2.05M derived: sum of 2 quarters · filed 2016-02-25 | $2.79M derived: sum of 3 quarters · filed 2016-02-25 | $3.13M 10-K · filed 2016-02-25 |
| 2013-09-30 | $955.00K 10-Q · filed 2014-11-04 | $1.70M derived: sum of 2 quarters · filed 2014-11-04 | $2.04M 10-Q · filed 2014-11-04 | $2.40M derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-06-30 | $742.00K 10-Q · filed 2014-08-05 | $1.08M 10-Q · filed 2014-08-05 | $1.45M derived: sum of 3 quarters · filed 2015-03-13 | $1.96M derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-03-31 | $340.00K 10-Q · filed 2014-05-05 | $705.00K derived: sum of 2 quarters · filed 2015-03-13 | $1.21M derived: sum of 3 quarters · filed 2015-03-13 | $2.87M derived: sum of 4 quarters · filed 2015-03-13 |
| 2012-12-31 | $365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $873.00K derived: sum of 2 quarters · filed 2015-03-13 | $2.53M derived: sum of 3 quarters · filed 2015-03-13 | $6.10M 10-K · filed 2015-03-13 |
| 2012-09-30 | $508.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $2.16M derived: sum of 2 quarters · filed 2013-11-12 | $5.73M 10-Q · filed 2013-11-12 | |
| 2012-06-30 | $1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-13 | $5.22M 10-Q · filed 2013-08-13 | ||
| 2012-03-31 | $3.57M 10-Q · filed 2013-05-15 | |||
| 2011-12-31 | $2.97M 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |